Compare Prudential Financial Inc (PRU) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Prudential Financial Inc trades at $114.26 (market cap $39.13B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Prudential Financial Inc is far larger — about 8× Travere Therapeutics Inc. Common Stock's market cap, and Prudential Financial Inc pays a 4.94% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 146 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PRU | TVTX | |
|---|---|---|
Market Cap | $39.13B | $4.88B |
Volume | 1,369,167 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $125.13 | $67.52 |
52-Week Low | $92.00 | $26.79 |
Typical Hold Time | 146 Days | 0 Days |
Enterprise Value | $67.90B | $5.01B |
Dividend Yield | 4.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.49, showing minimal daily movement (+0.09%). The stock presents mixed signals with bearish technical indicators but fundamentally attractive valuation metrics including a P/E of 10.28 and P/S of 0.61. Recent earnings show two consecutive quarterly beats, while the company executes strategic initiatives including a $185 million Alexforbes stake sale and rebranding to Prudential Wealth Advisors.
PRU offers value investment appeal with strong profitability metrics (12.46% ROE) and dividend income potential, though facing headwinds from bearish technical trends and mixed analyst sentiment. The company's strategic focus on core businesses and cost reduction provides upside potential, while interest rate sensitivity and competitive pressures remain key monitoring points for investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
